Novel Resistance Mechanisms to Second‐Generation <scp>EGFR</scp> Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in <scp>NSCLC</scp>
The study identified multiple genomic characteristics associated with primary and secondary resistance to first-line afatinib treatment in EGFR- and ERBB2-positive subpopulations.
Authors
- Wenqi Wu (ORCID: https://orcid.org/0000-0001-5985-2804)
- Jiani C. Yin (ORCID: https://orcid.org/0000-0002-9523-1930)
- Qiang Wu (ORCID: https://orcid.org/0000-0003-3922-5189)
- Yang Meng (ORCID: https://orcid.org/0000-0003-2811-6307)
- Min Gao (ORCID: https://orcid.org/0000-0003-1479-7914)
- Ya Ma (ORCID: https://orcid.org/0009-0002-8531-2013)
- Miaoqing Zhao (ORCID: https://orcid.org/0000-0001-9683-6483)
- Xiaoying Wu (ORCID: https://orcid.org/0000-0002-7913-118X)
- Fengwu Lin
Institutions
- Jilin University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- China-Japan Friendship Hospital (CN)
- Shandong Tumor Hospital (CN)
- Shandong First Medical University (CN)
- Union Hospital (CN)
- Hainan Medical University (CN)
- Genesee Community College (US)
Publication Details
- Journal
- Genes Chromosomes and Cancer
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1002/gcc.70088
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wu Jieping Medical Foundation